Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclobenzaprine + non-steroidal anti-inflammatory drugs
- Development stage
- Unknown
- Lead developer
- Beni-Suef University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination pharmacotherapy regimen consists of the skeletal muscle relaxant cyclobenzaprine and non-steroidal anti-inflammatory drugs (NSAIDs). It was evaluated in a clinical trial conducted by Beni-Suef University to treat masticatory muscle hyperactivity in patients with bruxism. Cyclobenzaprine is a centrally acting muscle relaxant that is thought to reduce tonic somatic motor activity by influencing both gamma and alpha motor systems, primarily within the brain stem; its effects may be mediated through antagonism of 5-HT2 receptors. NSAIDs provide complementary analgesic and anti-inflammatory effects by inhibiting the cyclooxygenase enzymes (COX-1 and COX-2), which are responsible for the synthesis of pro-inflammatory prostaglandins.
- Other names
- pharmacotherapy-Beni-Suef UniversityPharmacotherapy (Beni-Suef University study)
02
Targets
HTR2A (5-hydroxytryptamine receptor 2A)SERT (Sodium-dependent serotonin transporter)PGHS-1 (Prostaglandin G/H Synthase 1)NET (Norepinephrine Transporter)HTR2C (5-hydroxytryptamine 2C receptor)
Beyond the preview
Go deeper on cyclobenzaprine + non-steroidal anti-inflammatory drugs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclobenzaprine + non-steroidal anti-inflammatory drugs.